23
Participants
Start Date
March 29, 2016
Primary Completion Date
March 31, 2023
Study Completion Date
March 31, 2023
Atezolizumab
1200 mg Given IV
University of California, San Francisco, San Francisco
Collaborators (1)
Genentech, Inc.
INDUSTRY
Bladder Cancer Advocacy Network
OTHER
Conquer Cancer Foundation
OTHER
National Cancer Institute (NCI)
NIH
The V Foundation
OTHER
Lawrence Fong
OTHER